Buyback yield (TTM)
N/A
Shareholder yield (TTM)
N/A
5Y share count change
185.5%
Buyback spend (TTM)
N/A
Cumulative buybacks
$176.00K
Key takeaways
- Diluted share count is up 185.5% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
Dividend & buyback yield over time for Revolution Medicines (RVMD)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Revolution Medicines (RVMD)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Revolution Medicines (RVMD)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Revolution Medicines (RVMD)
Latest: $0.00
Overview
Revolution Medicines (RVMD) most recent annual buyback spend stands at $0.00 (2025).
Between 2018 and 2025, Revolution Medicines buyback spend plunged 100.0%, falling from $131.00K to $0.00.
Across the available history, buyback spend reached its high of $131.00K in 2018 and its low of $0.00 in 2017.
Revolution Medicines Buyback Spend 2025: $0.00
Revolution Medicines buyback spend in 2025 was $0.00.
Revolution Medicines Buyback Spend 2024: $0.00
Revolution Medicines buyback spend in 2024 was $0.00.
Revolution Medicines Buyback Spend 2023: $0.00
Revolution Medicines buyback spend in 2023 was $0.00.
Revolution Medicines Buyback Spend 2022: $0.00
Revolution Medicines buyback spend in 2022 was $0.00.
Revolution Medicines Buyback Spend 2021: $0.00
Revolution Medicines buyback spend in 2021 was $0.00.
See more financial history for Revolution Medicines (RVMD).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $0.00 | $118.39M | −$118.39M | — | 0.19B | +13.3% | |
| 2024 | $0.00 | $79.20M | −$79.20M | — | 0.17B | +48.2% | |
| 2023 | $0.00 | $61.77M | −$61.77M | — | 0.11B | +40.3% | |
| 2022 | $0.00 | $31.20M | −$31.20M | — | 0.08B | +10.7% | |
| 2021 | $0.00 | $20.72M | −$20.72M | — | 0.07B | +9.3% | |
| 2020 | $0.00 | $8.89M | −$8.89M | — | 0.07B | +82.6% | |
| 2019 | $45.00K | $3.16M | −$3.12M | 0.00% | 0.04B | 0.0% | |
| 2018 | $131.00K | $855.00K | −$724.00K | 0.01% | 0.04B | 0.0% | |
| 2017 | $0.00 | $141.00K | −$141.00K | — | 0.04B | — |
- 2025$0.00
- 2024$0.00
- 2023$0.00
- 2022$0.00
- 2021$0.00
- 2020$0.00
- 2019$45.00K
- 2018$131.00K
- 2017$0.00
Buybacks vs stock-based compensation for Revolution Medicines (RVMD)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.00×.
Buybacks vs dividends (share of cash returned) for Revolution Medicines (RVMD)
How Revolution Medicines splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Revolution Medicines, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $719.66M | |
| $216.35M | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $719.66M
- $216.35M
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $0.00 (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation